Bevacizumab in the treatment of colorectal cancer

Author： Mulcahy Mary F   Benson III Al B  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.5, Iss.7, 2005-07, pp. : 997-1005

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of bevacizumab in colorectal cancer: understanding its benefits and limitations

By Mulder Karen   Scarfe Andrew   Chua Neil   Spratlin Jennifer  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 3, 2011-03 ,pp. : 405-413

Informa Healthcare

Access to resources Recommend Favorite

Cetuximab in the treatment of patients with colorectal cancer

By Garrett Christopher R   Eng Cathy  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 7, 2011-07 ,pp. : 937-949

Informa Healthcare

Access to resources Recommend Favorite

The developing trend of monoclonal antibodies in the treatment of colorectal cancer

By Elfiky Aymen A   Saif Muhammad W  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 6, 2007-06 ,pp. : 871-883

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia

By Kanellopoulou Theoni  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 9, 2013-09 ,pp. : 1315-1323

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab for the treatment of high-grade glioma

By Khasraw Mustafa   Simeonovic Marcelle   Grommes Christian  

Expert Opinion on Biological Therapy, Vol. 12, Iss. 8, 2012-08 ,pp. : 1101-1111

Informa Healthcare

Access to resources Recommend Favorite